Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02927340
Title A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Massachusetts General Hospital
Indications

lung non-small cell carcinoma

Therapies

Lorlatinib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST